getting to the heart of the matter
Novel therapeutics and diagnostics targeting the multi-factorial root causes of CVD
CVD and
the Arterez approach
Cardiovascular disease (CVD), particularly coronary heart disease (CHD) remains the No. 1 disease killer and is rising in the world. By 2030, 23.6 million people are predicted to die from CVD. In the U.S., 42% of all deaths annually are a direct result of CVD; one person dies every 33 seconds from heart disease and it is the leading cause of death for all Americans age 35 and older.
While current symptom-targeted drugs are at best palliative, Arterez has developed a novel 3x compound, synthetic oral therapy and companion diagnostic panel targeting the multi-factorial root causes of CVD.
"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."
Dr. Joe Tunac
Offerings and IP Summary
Primary Offerings
IP Matter Description
Embotricin™
A rationally synthesized, triple compound, oral therapy with unique mechanisms of action targeting the root causes of CVD proven to prevent and reverse arterial plaques, the hallmark of CVD.
GlycoCardia™
A therapeutic aide and series of diagnostic panels that provide specific information on the associated pathology and risk factors of CVD diseases and stages based on our Glycalyx Detritus Fingerprint™ technology.
Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
Glycocalyx Disruption.
Biomarkers of Vascular Disease.
Methods and Compositions for Reversing
Disruption of the Glycocalyx, Inflammation and
Oxidative Damage.
(Draft - to be published Q2, 2020) Natural Animal Model for CVD and Inflammation.
